The Oncologist, Vol. 1, No. 6, 398–398,
December 1996
© 1996 AlphaMed Press
SPECIAL SECTION
PATIENT CARE |
From The Bethesda Post
 |
ABSTRACT
|
|---|
The Oncologist is pleased to feature news FROM THE BETHESDA POST, featuring high-priority National Cancer Institute clinical trials which are now accruing patients at the National Institutes of Health Clinical Center. There will be information on how to refer patients who may benefit from experimental cancer treatments. Once accepted on protocol, participating patients receive experimental treatment as well as travel to Bethesda free of charge.
Watch for forthcoming POSTS from Berlin, Amsterdam, Boston and around the globe in future issues of The Oncologist.
|
NEW VACCINE STUDIES IN SOLID TUMORS
|
|---|
The intramural clinical program in Bethesda is sponsoring a number of new studies exploring the role of vaccines in cancer treatment. Some of these studies take advantage of the association between the mutation of certain oncogenes and tumor suppressors and the development of cancer.
For example, more than 50% of solid tumors are associated with p53 gene mutations, and more than 20% of solid tumors are associated with Ras gene mutations. There is laboratory evidence that peptide products of these genes are processed and recognized by the T cells, the cells responsible for tissue rejection in man. For this reason, we are studying whether the p53 and Ras proteins can be targets for specific cancer vaccination in patients who carry genetic mutations, in one of these genes, in their tumors.
Patients eligible for the trial include:
- Patients with advanced disease who failed standard therapy, including: gastrointestinal cancer (colon, gastric, esophagus, and pancreas), non-small cell lung cancer, breast and ovarian cancers, bladder and kidney cancer, and thyroid cancer.
- Patients with diseases that could be treated on an adjuvant basis, including: adenocarcinoma of the lung stage II or III after surgery or radiation therapy, SCLC, limited or extensive disease in CR, colorectal cancer Duke C patients who received appropriate adjuvant chemotherapy, fully resected pancreatic or fully resected recurrent colorectal carcinoma. The cost of all therapy as well as travel to and from Bethesda is covered for patients on study.
For more information, or for patient referral, contact Dr. Samir N. Khleif at telephone: 301-594-0210; fax: 301-496-0047; e-mail: khleif{at}nih.gov
Top
Abstract
New Vaccine Studies in...
